These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 523335)

  • 1. Effects of selective monoamine oxidase (MAO) inhibitors on conditioned avoidance responses (CAR) of rats.
    Timár J; Knoll B; Gyarmati Z; Knoll J
    Pol J Pharmacol Pharm; 1979; 31(4):251-60. PubMed ID: 523335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of selective MAO inhibitors on the conditioned avoidance response of Wistar rats.
    Knoll B; Held G; Gyarmati Z
    Pol J Pharmacol Pharm; 1977; 29(3):291-6. PubMed ID: 887504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The presence of the type A form of monoamine oxidase within nigrostriatal dopamine-containing neurons.
    Demarest KT; Smith DJ; Azzaro AJ
    J Pharmacol Exp Ther; 1980 Nov; 215(2):461-8. PubMed ID: 7441510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].
    Miklya I
    Neuropsychopharmacol Hung; 2008 Mar; 10(1):15-22. PubMed ID: 18771016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J
    Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I; Youdim MB; Finberg JP
    J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.
    Knoll J
    J Neural Transm Suppl; 1987; 25():45-66. PubMed ID: 2828537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of MAO-A activity enhances behavioural activity of rats assessed using water maze and open arena tasks.
    Barbelivien A; Nyman L; Haapalinna A; Sirviö J
    Pharmacol Toxicol; 2001 Jun; 88(6):304-12. PubMed ID: 11453370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway.
    Aluf Y; Vaya J; Khatib S; Loboda Y; Finberg JP
    Neuropharmacology; 2013 Feb; 65():48-57. PubMed ID: 22982254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of MAO inhibitors on the uptake and metabolism of dopamine in rat and human brain.
    Tekes K; Tóthfalusi L; Gaál J; Magyar K
    Pol J Pharmacol Pharm; 1988; 40(6):653-8. PubMed ID: 3152003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of monoamine oxidase inhibitors on striatonigral dynorphin system: a study with deprenyl and clorgyline.
    Sivam SP
    Neuropeptides; 1993 Jul; 25(1):35-45. PubMed ID: 7692341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of dopamine release by selective inhibitors of MAO-B.
    Finberg JP; Lamensdorf I; Armoni T
    Neurobiology (Bp); 2000; 8(2):137-42. PubMed ID: 11061211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats.
    Finberg JP; Wang J; Goldstein DS; Kopin IJ; Bankiewicz KS
    J Neurochem; 1995 Sep; 65(3):1213-20. PubMed ID: 7643100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Medicamentous strategy for improving the quality of life in the senescence].
    Knoll J
    Wien Med Wochenschr Suppl; 1986; 98():1-18. PubMed ID: 3097965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-dependent effects of the 2'-methyl analog of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: prevention by inhibitors of monoamine oxidase B.
    Finnegan KT; Irwin I; Delanney LE; Langston JW
    J Pharmacol Exp Ther; 1995 May; 273(2):716-20. PubMed ID: 7752075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum.
    Paterson IA; Juorio AV; Berry MD; Zhu MY
    J Pharmacol Exp Ther; 1991 Sep; 258(3):1019-26. PubMed ID: 1679846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum.
    Butcher SP; Fairbrother IS; Kelly JS; Arbuthnott GW
    J Neurochem; 1990 Sep; 55(3):981-8. PubMed ID: 2117053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys.
    Di Monte DA; DeLanney LE; Irwin I; Royland JE; Chan P; Jakowec MW; Langston JW
    Brain Res; 1996 Oct; 738(1):53-9. PubMed ID: 8949927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of co-administration of subchronic lithium pretreatment and acute MAO inhibitors on extracellular monoamine levels and the expression of contextual conditioned fear in rats.
    Kitaichi Y; Inoue T; Nakagawa S; Izumi T; Koyama T
    Eur J Pharmacol; 2006 Feb; 532(3):236-45. PubMed ID: 16487506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline.
    Zsilla G; Földi P; Held G; Székely AM; Knoll J
    Pol J Pharmacol Pharm; 1986; 38(1):57-67. PubMed ID: 3020531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.